The Form 4 filing, an SEC report of an insider's stock trades, was filed on November 12, 2026. It lists November 9, 2026, as the date of both sales by Justin B. Klee, co-chief executive officer of Amylyx Pharmaceuticals (AMLX).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-09 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 100,000 |
| Price | $29.84 |
| Total Transaction Value | $2,983,838.40 |
| Insider | |
| Ticker Symbol | AMLX |
| Company | Amylyx Pharmaceuticals, Inc. |
| Insider Name | Klee Justin B. |
| Insider Title | Co-Chief Executive Officer |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 3,513,056 |
| Position Size Change | 2.77% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The filing lists two sales, covering 100,000 shares in total.
What was the average price of the transaction?
The average sale price was $29.84 per share across both transactions. Separate prices for each of the two sales were not provided.
How did this transaction affect the insider's holdings?
Justin B. Klee sold 100,000 shares and reported owning 3,513,056 shares afterward. The shares sold made up 2.77% of his reported share balance before the sales.
What's the total transaction value?
The two sales had a total value of $2,983,838.40. This is the combined value of all 100,000 shares sold. Separate dollar totals for each sale were not provided.
Are there any special circumstances around this transaction?
The transaction details include a Rule 10b5-1 trading-plan reference. Such plans set trade instructions in advance. Footnote text was not provided, so it is unclear whether the reference covers both sales. The plan's adoption date, trading schedule, and other terms are unknown. A plan reference alone does not show whether all of the rule's requirements were met.
For research purposes only; not investment advice.